NEW YORK CITY (dpa-AFX) - Merck KGaA (MKGAY.PK), and Pfizer (PFE) announced the US FDA has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma, a rare and aggressive type of skin cancer.
The clinical development program for avelumab now includes more than 1,000 patients who have been treated across more than 15 tumor types.
Copyright RTT News/dpa-AFX